• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Coronary Sinus Neuropeptide Y Levels and Adverse Outcomes in Patients With Stable Chronic Heart Failure

byJack LennonandAliya Ramjaun
January 12, 2020
in Cardiology, Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Angiotensin receptor blockers may reduce the incidence of epilepsy in patients with hypertension

#VisualAbstract: Dapagliflozin slows disease progression in patients with heart failure with preserved ejection fraction

Antihypertensives reduce the rate of progressive aortic root dilation in Marfan syndrome

1. In patients with stable heart failure, adrenergic co-transmitter neuropeptide Y (NPY) levels can identify patients at risk of adverse outcomes related to hyperadrenergic activation

Evidence Rating Level: 2 (Good)

The adrenergic co-transmitter neuropeptide Y (NPY) is one of the neurotransmitters released by cardiac sympathetic nerve terminals, and may represent an important biomarker in the prognostication of patients with chronic heart failure (CHF). This prospective cohort study investigated coronary sinus (CS) NPY levels in 105 patients with stable CHF at the time elective cardiac resynchronization therapy (CRT) device implantation to determine the role of NPY levels in predicting adverse outcomes, including chronic heart failure hospitalization, death, orthotopic heart transplantation and ventricular assist device placement. The mean left ventricular ejection fraction (LVEF) of the sample was 26% (SD 7%). Patients were optimized with beta-blockers (90%), angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or nitrate/hydralazine combination (95%), and/or aldosterone antagonist (25%) prior to treatment. Researchers found that for patients with CS NPY levels greater than 130 pg/mL, the hazard ratio for event-free survival was increased (HR 9.5, 95% CI 2.92 to 30.5, p<0.001). Eight deaths and 28 heart failure hospitalizations were reported. Following CRT device implantation and follow-up, 59 patients were considered CRT responders at six-months post-treatment. Baseline NPY levels were not significantly different between responders and non-responders (difference = – 2.2 pg/mL, p = 0.76). Following molecular analyses of CHF patients and organ donor controls, NPY levels were associated with eGFR (rs = -0.36, p<0.001), N-terminal-pro hormone brain natriuretic peptide (rs = 0.33, p = 0.004), and left ventricular diastolic dimension (rs = -0.35, p<0.001), but not LVEF, functional status, age, or CRT response. Adjusting for LVEF, eGFR, and age to determine event-free (left ventricular assist device, cardiac transplant, death) survival for CS NPY levels greater than 130 pg/mL suggested similar findings to the previous analyses. Significantly reduced mean (SD) NPY protein was noted in cardiomyopathy (13.7 [7.6]) compared to controls (31.4 [3.7]; p<0.001) in stellate ganglia neurons and, with similar mRNA levels between these groups, suggests that CHF patients experience increased release from stellate ganglia neurons. This study therefore suggests that CS NPY levels may be associated with outcomes in stable CHF patients undergoing CRT, where elevated neuronal activity may serve as a mediating mechanism in these patients.

Click to read the study in JAMA Cardiology

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: aldosterone antagonistangiotensin-converting enzyme inhibitorbeta blockerCRTLVEFneuropeptide Y (NPY)
Previous Post

#VisualAbstract: A Texting Intervention in Latino Families to Reduce ED Use

Next Post

Clinician vs Patient Reporting of Baseline and Post-Baseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials

RelatedReports

Patient Basics: Seizure
Chronic Disease

Angiotensin receptor blockers may reduce the incidence of epilepsy in patients with hypertension

October 24, 2022
#VisualAbstract: Dapagliflozin slows disease progression in patients with heart failure with preserved ejection fraction
StudyGraphics

#VisualAbstract: Dapagliflozin slows disease progression in patients with heart failure with preserved ejection fraction

October 5, 2022
Shorter time to angioplasty may improve heart attack outcomes
Cardiology

Antihypertensives reduce the rate of progressive aortic root dilation in Marfan syndrome

September 21, 2022
Quick Take: Association of African Ancestry with Electrocardiographic Voltage and Concentric Left Ventricular Hypertrophy: The Dallas Heart Study
Cardiology

Cardiovascular magnetic resonance imaging phenotype with pathology-frequent late gadolinium enhancement associated with high-risk of ventricular arrhythmic and heart failure events

September 19, 2022
Next Post
American College of Physicians releases principles to guide patient partnership in health care

Clinician vs Patient Reporting of Baseline and Post-Baseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials

Cerebral protection device effective in patients undergoing transcatheter aortic valve implantation

2 Minute Medicine Rewind January 13, 2020

Mortality and Health Care Utilization Among Medicare Patients Undergoing Emergency General Surgery vs Those With Acute Medical Conditions

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
  • #VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options